Diabetes

  • Type 2 diabetes is a major risk factor for the development of cardiovascular disease and cerebrovascular incidents. A substantial body of evidence has demonstrated that the proper management of blood glucose in people with diabetes can inhibit the progression of microvascular diseases such as retinopathy and nephropathy.

    Load more

    Type 2 diabetes is a major risk factor for the development of cardiovascular disease and cerebrovascular incidents. A substantial body of evidence has demonstrated that the proper management of blood glucose in people with diabetes can inhibit the progression of microvascular diseases such as retinopathy and nephropathy.

    In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, the overall mortality significantly increased by strict control of blood glucose (target HbA1c <6%) compared with a less stringent control (target HbA1c of approximately 7%). Strict glucose control resulted in a significantly higher likelihood of developing severe hypoglycaemia, while severe hypoglycaemia was itself associated with death due to CVD.

    Load Less

Videos

Type 2 Diabetes (T2D)

Type 2 Diabetes Mellitus

CV Outcomes in Diabetes

Risk reduction with antihyperglycemics

Cardiovascular (CV) disease remains the leading cause of morbidity and mortality in patients with type 2 diabetes (T2D).

The opportunity for CV disease prevention in patients with T2D has recently expanded with antihyperglycemic agents demonstrating significant reductions in the risk of major adverse cardiovascular events (MACE). Although the exact mechanisms of CV benefit remain uncertain, they appear to be unrelated to the direct glucose-lowering effects. These agents have triggered a shift beyond glucose control, to a broader strategy of comprehensive CV risk reduction.

CV specialists are well-positioned to play a key role in managing patients with T2D including screening, aggressively treating CV risk factors, and incorporating the use of antihyperglycemic agents into routine practice.


The Radcliffe diabetes and CVD risk program is supported by an educational grant from Novo Nordisk.

novo nordisk

Section Editor

Professor Mikhail N Kosiborod

Saint Luke's America Heart Institute, Kansas City, MO, US

  • Cardiovascular and renal outcomes with empagliflozin

    Patients with HF were randomised to empagliflozin or placebo, in addition to recommended therapy. Those in the empagliflozin group had a lower risk of CV death or hospitalisation for HF, regardless of the presence or absence of diabetes.

    Packer M, Anker SD, Butler J, et al. N Engl J Med 2020; epub ahead of press.
  • SGLT2 inhibitors in patients with heart failure

    This meta-analysis demonstrated the effects of empagliflozin and dapagliflozin on hospitalisations for HF were consistent in both trials and suggest that these agents also improve renal outcomes and reduce all-cause and cardiovascular death in...

    Zannad F, Ferreira JP, Pocock SJ, et al. Lancet 2020;epub ahead of press.
  • A metabolic handbook for the COVID-19 pandemic

    An overview of why pre-existing metabolic conditions, eg type 2 diabetes and hypertension, may be important risk factors for severe COVID-19, how metabolism might be harnessed to defend against infection, and the long-term metabolic consequences...

    Ayres JS. Nat Metab 2020;2:572–85.
  • 2020 expert consensus decision pathway

    The potential of new anti-diabetes drugs has led CV specialists to be more active in prescribing glucose-lowering therapies. This updated guideline provides guidance on the use of specific agents for reducing CV risk in patients with T2D.

    Das SR, Everett BM, Birtcher KK, et al. J Am Coll Cardiol 2020;76:1117–45.

Pages

Clinical publications

Pages

Ongoing trials

Pages

Review articles

Pages

Guidelines

Pages

Pages

Subscribe to RSS - Diabetes